These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36265994)

  • 1. Novel Considerations in Surgical Management of Individuals with Pancreatic Adenocarcinoma.
    Barnes CA; Tsai S
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):979-994. PubMed ID: 36265994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved outcomes for borderline resectable adenocarcinoma of the pancreas after neoadjuvant chemotherapy in a community cancer center.
    Curto EM; Kaza AG; Sturdevant DA; Tuvin DM; Ganai S; Sticca RP
    Am J Surg; 2022 Dec; 224(6):1426-1431. PubMed ID: 36372580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis.
    Brown ZJ; Heh V; Labiner HE; Brock GN; Ejaz A; Dillhoff M; Tsung A; Pawlik TM; Cloyd JM
    Br J Surg; 2022 Dec; 110(1):34-42. PubMed ID: 36346716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of borderline resectable pancreatic cancer.
    Cooper AB; Tzeng CW; Katz MH
    Curr Treat Options Oncol; 2013 Sep; 14(3):293-310. PubMed ID: 23793524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.
    Tempero MA; Malafa MP; Behrman SW; Benson AB; Casper ES; Chiorean EG; Chung V; Cohen SJ; Czito B; Engebretson A; Feng M; Hawkins WG; Herman J; Hoffman JP; Ko A; Komanduri S; Koong A; Lowy AM; Ma WW; Merchant NB; Mulvihill SJ; Muscarella P; Nakakura EK; Obando J; Pitman MB; Reddy S; Sasson AR; Thayer SP; Weekes CD; Wolff RA; Wolpin BM; Burns JL; Freedman-Cass DA
    J Natl Compr Canc Netw; 2014 Aug; 12(8):1083-93. PubMed ID: 25099441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
    Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
    Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence.
    Brown ZJ; Ruff SM; Cloyd JM
    Curr Opin Pharmacol; 2022 Dec; 67():102305. PubMed ID: 36223686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
    Wanebo HJ; Glicksman AS; Vezeridis MP; Clark J; Tibbetts L; Koness RJ; Levy A
    Arch Surg; 2000 Jan; 135(1):81-7; discussion 88. PubMed ID: 10636353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
    White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
    Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
    Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
    BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
    Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
    Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
    Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
    BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
    Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
    Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.